kirapharma.com Open in urlscan Pro
76.76.21.21  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Science
Pipeline
Pipeline
KP104
About Us
News
Presentations
Science
Pipeline
Pipeline
KP104
About Us
News
Presentations


PIONEERING A WORLD FREE FROM COMPLEMENT DISEASE

Explore

Our Mission

ADVANCING TRANSFORMATIVE THERAPIES FOR PATIENTS WITH COMPLEMENT-MEDIATED
DISEASES


ADVANCING TRANSFORMATIVE THERAPIES FOR PATIENTS WITH COMPLEMENT-MEDIATED
DISEASES

Named after a patient with complement 3 glomerulopathy (C3G), Kira
Pharmaceuticals is driven by the opportunity for impact with the mission to
advance transformative therapies for patients around the world with
complement-mediated diseases.
Kira Pharmaceuticals is a clinical-stage biotechnology company pioneering a
world free from complement disease. Enabled by its LOGIC platform, the company
has developed a robust pipeline of nine (9) novel complement assets since its
inception in 2017, focused on validated targets across the complement cascade.
With an experienced team of complement biology experts, drug developers, protein
engineers and leaders from across the pharma and biotech industry, Kira
Pharmaceuticals is uniquely positioned to tackle some of the most complex and
toughest challenges in the complement space and to deliver first-in-class and
best-in-class therapies to transform the lives of patients.
The Challenge


COMPLEXITIES OF COMPLEMENT

The complement systems regulates important immune functions, but its complex
biology has historically posed a challenge for drug development.

The complement system is complex and implicated in a large number of autoimmune
and inflammatory conditions across hematology, nephrology, neurology,
dermatology, ophthalmology and many other disease areas.  However, given the
complex biology and abundance of proteins involved in the complement system, it
has historically been challenging to develop effective and convenient therapies
to modulate the complement system.

The Science
our solution


WORLD RENOWNED EXPERTISE AND LOGIC-BASED APPROACH

Deep complement knowledge combined with precise drug design and associated
validation tools optimize assets for clinical success


Founded and advised by world renowned complement biology experts and in
collaboration with or op-tier research institutions both in the US and Europe
through ongoing sponsored research agreements, Kira Pharmaceuticals is
leveraging its proprietary LOGIC platform (Lead identification, Optimization and
Attribute Generation, In-vivo Confirmation) to overcome key challenges of
developing complement therapeutics and increasing their probability of success
in the clinic.  We are moving from complexity to clarity to improve the lives of
patients.

"Anti-complement drugs have great potential in treating a variety of human
immunological disorders, and Kira’s approach of bringing together deep
complement expertise with seasoned and experienced drug developers and protein
engineers is a powerful combination to develop next-generation therapeutics that
could transform the lives of patients with complement-mediated disease."
Wenru Song, MD, PhD
President & Head of R&D, Co-founder
More on Our Science and LOGIC approach


OUR PIPELINE

Kira Pharmaceuticals is pioneering the field, developing a broad pipeline of
compelling therapies designed to achieve better, longer acting and targeted
immune modulation across a range of complement diseases. With our lead asset
entering Phase 2 and nine assets in the pipeline, we are advancing the next
generation of complement therapies. These assets are investigational agents and
have not yet been approved by any Health Authority, such as the FDA.

assets
indications
trials
vision
See our pipeline


ABOUT OUR TEAM

Kira’s experienced team includes established drug developers and protein
engineers, world-renowned experts in complement biology and leaders from across
the pharma and biotech industry. The team is augmented by well-respected
academic collaborators at major US and European research institutions alongside
an outstanding Scientific Advisory Board with international reputations in
complement biology and immunology.

About Us
Kira - Where established drug developers and world renown experts in complement
biology come together to pioneer a world free from complement disease


LATEST NEWS

Stay up to date with Kira Pharmaceutical’s latest news and updates.
News · Kira Pharmaceuticals

KIRA PHARMACEUTICALS PRESENTS COMPLETE DATA FROM PHASE 1 SYNERGY-1 TRIAL OF
KP104 AT AMERICAN SOCIETY FOR NEPHROLOGY KIDNEY WEEK 2022

Biomarker data demonstrates proof-of-concept for KP104’s dual-targeting... 
Nov 03, 2022
Read full article
News · Kira Pharmaceuticals

KIRA PHARMACEUTICALS TO PRESENT FIRST-IN-HUMAN CLINICAL DATA AT AMERICAN SOCIETY
FOR NEPHROLOGY KIDNEY WEEK 2022

Phase 1 biomarker data confirms proof of mechanism with dose-dependent and... 
Oct 17, 2022
Read full article
News · Kira Pharmaceuticals

KIRA PHARMACEUTICALS ANNOUNCES IND APPROVAL FROM CHINESE NMPA FOR PHASE 2
EVALUATION OF KP104 IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (October 17, 2022) – Kira... 
Oct 16, 2022
Read full article
All News


PRESENTATIONS

See our latest presentations and posters.
Poster

SYNERGY-1: A PHASE 1, FIRST-IN-HUMAN, SAFETY, TOLERABILITY, IMMUNOGENICITY, PK
AND PD STUDY OF KP104 IN ESCALATING SINGLE AND MULTIPLE DOSES IN HEALTHY
SUBJECTS

Nov 05, 2022

Poster

EMCHD 2022: DESIGN AND CHARACTERIZATION OF KP104, A BIFUNCTIONAL ANTI-C5 MAB AND
FH1-5 FUSION PROTEIN THAT SYNERGISTICALLY INHIBITS ALTERNATIVE AND TERMINAL
PATHWAYS OF COMPLEMENT ACTIVATION

Aug 26, 2022

Poster

EMCHD 2022: THERAPEUTIC EFFICACY OF A BI-FUNCTIONAL C5 MAB-FH1-5 FUSION PROTEIN
IN A MOUSE MODEL OF RAPIDLY PROGRESSING LETHAL C3 GLOMERULOPATHY (C3G)

Aug 26, 2022

All Presentations


GET IN TOUCH WITH US!

Get in touch to learn more about our LOGIC discovery platform and pipeline.

Contact

SciencePipelineAbout UsNewsPresentations
Kira Pharmaceuticals (US) LLC
245 Main Street
12th FL
Cambridge, MA 02142



info@kirapharma.com
Financial Conflict of Interest Policy | Terms of Use & Privacy Policy | © 2022
Kira Pharma Company. All Rights Reserved.